Indy Hematology Review

http://www.indyhematologyreview.com/

 

Indy Hematology Review
Avatar

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk Stratification and Treatment

By Indy Hematology Review FEATURING Ayalew Tefferi
By Indy Hematology Review FEATURING Ayalew Tefferi
742 views
April 18, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
2023
19:34
Indy Hematology Review

2023 Management of Long-Term Survivors of Hematologic Malignancies

Feat. S. Garofalo
26:05
Indy Hematology Review

Understanding and Managing Immune Effector Cell Toxicities in Hemato…

Feat. D. Reeves
73:56
Indy Hematology Review

Indy Hematology Review 2023: Expert Case Discussions

Feat. M. Wiemann, S. Usmani, J. Mikhael, M. Lunning, S. Treon, T. Phillips, J. Woyach
21:29
Indy Hematology Review

Indy Hematology Review 2023: Emerging Therapies in Hematologic Malig…

Feat. R. Birhiray
24:53
Indy Hematology Review

Emerging and Current Treatment of Amyloidosis and Waldenstrom’s Macr…

Feat. M. Gertz
26:02
Indy Hematology Review

Recognizing Toxicities of Oral Oncolytics in the Management of Hemat…

Feat. K. Orbaugh
31:33
Indy Hematology Review

Sickle Cell Disease and Clotting Disorders of the Blood in 2023

Feat. C. Kessler
31:51
Indy Hematology Review

Managing Newly Diagnosed MM in 2023

Feat. S. Usmani
22:30
Indy Hematology Review

Targets and Treatments of MPNs in 2023

Feat. R. Mesa
32:06
Indy Hematology Review

Current and Emerging Therapies for AML and MDS

Feat. R. Larson
24:33
Indy Hematology Review

Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…

Feat. J. Woyach
31:25
Indy Hematology Review

Jumping on a Moving Bullet Train: Emerging Treatments for Hodgkin Ly…

Feat. M. Lunning
34:28
Indy Hematology Review

Advancing Therapeutic Outcomes in Aggressive B and T Cell Lymphomas

Feat. T. Phillips
19:42
Indy Hematology Review

Beyond Hyperviscosity: 80 Years and Counting - Treatment of Waldenst…

Feat. S. Treon
18:27
Indy Hematology Review

DEBATE: Why Not to Transplant When MRD Has Been Achieved After Initi…

Feat. J. Mikhael
15:53
Indy Hematology Review

DEBATE: Transplanting the MRD- Myeloma Patients for a Deeper Remissi…

Feat. S. Usmani
06:33
Indy Hematology Review

Indy Hematology Review 2023: Take Home Messages for MDS & AML

Feat. R. Komrokji
06:36
Indy Hematology Review

Indy Hematology Review 2023: Recent Important Results for Adult ALL

Feat. C. Schiffer
04:15
Indy Hematology Review

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

Feat. M. Gertz
28:07
Indy Hematology Review

Controversies and Recommendations for the Treatment of ALL and Lymph…

Feat. W. Stock
38:55
Indy Hematology Review

Managing Indolent and Mantle Cell Lymphomas With Targeted and Cellul…

Feat. G. Salles
24:21
Indy Hematology Review

Emerging Therapies for R/R CLL

Feat. W. Wierda
31:43
Indy Hematology Review

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Feat. A. Tefferi
24:37
Indy Hematology Review

Recent Updates on the Treatment of Polycythemia Vera

Feat. A. Fleischman
16:23
Indy Hematology Review

Updates on the Treatment of Myelofibrosis and FGFR-Mutated Myeloid N…

Feat. A. Fleischman
32:03
Indy Hematology Review

Emerging and Current Treatment of MM: What Should We Know and What S…

Feat. K. Anderson
31:16
Indy Hematology Review

Hematopoietic Stem Cell Transplantation: State of the Art in 2023

Feat. R. Childs
28:25
Indy Hematology Review

Managing the Benign Hematology Consult: Treatment Recommendations fo…

Feat. C. Kessler
28:41
Indy Hematology Review

Improving Outcomes With Current Therapies in AML and Acute Promyeloc…

Feat. M. Tallman
27:52
Indy Hematology Review

The Oracle of Apollo in Indianapolis: Prognosis and Treatment in MDS

Feat. R. Stone
27:16
Indy Hematology Review

Resistant or Recurrent CML and Prospective Discontinuation

Feat. R. Larson